Clinical trials: Cancer Therapy-related Cardiovascular Toxicity
Cardiac Toxicity, Malignant Neoplasm
MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy With Exercise Capacity Addendum
This trial studies how well magnetic resonance imaging (MRI) works in detecting heart damage in patients with cancer receiving chemotherapy.
- Conditions
- Cardiac Toxicity, Malignant Neoplasm, Breast Cancer
- Trial name
- NCT01719562
- Testing
- Magnetic resonance imaging, Physical Activity, Healthy Living
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Wake Forest University Health Sciences
Heart Failure, Breast Cancer
Cardiac Toxicity in Medical Treatment of Breast Cancer
This study will describe the epidemiology including prognosis of heart failure related to treatment with anthracycline and trastuzumab for breast cancer.
- Trial name
- CaTOB (NCT02440620)
- Where
- Denmark
- Volunteers
- 45 people
- Sponsor
- Odense University Hospital
HER2-positive Breast Cancer, Targeted Therapy
Cardiotoxicity of Targeted Therapy for HER-2 Positive Breast Cancer Patients at High Altitude
This is a prospective, multicenter, cohort study aiming to explore the cardiotoxicity of targeted therapy for HER-2 positive breast cancer patients who lives in high altitude area.
- Conditions
- HER2-positive Breast Cancer, Targeted Therapy, Cardiac Toxicity, High Altitude
- Trial name
- NCT05063643
- Testing
- High altitude
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Affiliated Hospital of Qinghai University
Childhood Cancer, Cardiac Toxicity
Translating ECHOS2 Into an mHealth Platform
Childhood cancer survivors are at an increased risk of cardiac toxicity due to prior anti-cancer therapy. However, adherence to cardiac screening in this population remains low.
- Conditions
- Childhood Cancer, Cardiac Toxicity, Pediatric Cancer
- Trial name
- ECHOS2 (NCT05923242)
- Testing
- Computerized Intervention Authoring Software (CIAS)
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Washington University School of Medicine
Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumors from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
- Conditions
- Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma
- Trial name
- NCT00004036
- Testing
- sargramostim, amifostine trihydrate, carboplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cleveland Clinic
Melanoma Stage III or IV
CARDiac Toxicity Following ImmunOtherapy Treatment for Melanoma
People who develop a type of skin cancer known as 'melanoma' are often treated with immunotherapy. The type of immunotherapy used for patients with melanoma is known as Immune Checkpoint Inhibitors (ICI).
- Trial name
- CARD-IO (NCT06605833)
- Testing
- 12-Lead ECG, Transthoracic Echocardiogram, Cardiac MRI
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Cancer
Cardiac Aggressive Risk Mitigation in Thoracic Radiotherapy (CARMA) Trial
The purpose of this study is to examine adherence to cardio-oncology consultation.
- Trial name
- CARMA (NCT05403736)
- Testing
- Cardiac Aggressive Risk MitigAtion Plan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Breast Cancer Female
Preventing Breast Cancer Therapy-related Cardiovascular Toxicity With a Daily-adapted Program With Mhealth Support
ATOPE-PRO, was developed with the intention of consolidating the integration of an innovative system for the prevention of cancer therapy-related cardiovascular toxicity (CTR-CVT) in the continuum care of women with breast cancer…
- Trial name
- ATOPE-PRO (NCT06518200)
- Testing
- Individualised health recommentations, General health recommendations, Individualised physical exercise program
- Where
- Spain
- Volunteers
- 102 people
- Sponsor
- Universidad de Granada
Breast Cancer, Lymphoma, Large B-Cell, Diffuse
Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines
As the cancer-related prognosis improves thanks to recent advances in cancer-targeted therapies, the prognostic burden of chemotherapy-related complications - including cardiotoxicity - is increasingly recognised.
- Conditions
- Breast Cancer, Lymphoma, Large B-Cell, Diffuse, Cardiotoxicity, Left Ventricular Dysfunction
- Trial name
- CONTROL (NCT05728632)
- Testing
- Nebivolol
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Giulio Stefanini
Ventricular Dysfunction, Cardiotoxicity
Optimising Screening for the Cardiotoxic Effects of Cancer Therapy
Cancer is a major worldwide health problem, with around 330.000 new annual cases only in the UK. Improved survival rates due to better treatments have lead to an increase in the prevalence of chemotherapy related cardiac disease…
- Conditions
- Ventricular Dysfunction, Cardiotoxicity, Chemotherapeutic Toxicity
- Trial name
- NCT06817044
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- Barts & The London NHS Trust
Breast Cancer, Cardiac Toxicity
Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab
RATIONALE: Studying samples of blood and tissue in the laboratory from women receiving doxorubicin and trastuzumab for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers for…
- Conditions
- Breast Cancer, Cardiac Toxicity, Cardiovascular Complications
- Trial name
- PACE in BC (NCT00875238)
- Testing
- trastuzumab, doxorubicin hydrochloride, polymorphism analysis
- Where
- 4 sites in United States
- Volunteers
- 133 people
- Sponsor
- Vanderbilt University
Cardiovascular Diseases, Cardiotoxicity
Cancer Treatment Related Cardiovascular Toxicity: Comprehensive Myocardial and Vascular Phenotyping
Observational prospective cohort study designed to assess the mechanisms of fluoropyrimidine induced cardiovascular toxicity.
- Conditions
- Cardiovascular Diseases, Cardiotoxicity, Fluorouracil Adverse Reaction, Malignancy
- Trial name
- PC-TOX (NCT06048458)
- Testing
- Cardiovascular magnetic resonance with stress perfusion, CT coronary angiography, Retinal OCT angiography
- Where
- United Kingdom
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University College, London
Cancer Therapy-related Cardiovascular Toxicity
Correlation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy and the Preventive of Probiotics
The purpose of this study was to explore the relationship between early myocardial injury caused by tumor drug therapy and intestinal microbial structure changes by echocardiographic two-dimensional speckle tracking technique and…
- Trial name
- NCT05730777
- Testing
- Bifidobacterium Bifidum Oral Capsule, Cisplatin, Carboplatin
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University Third Hospital
Cardiac Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment (PREDICT)
The goal of this clinical research study is to learn if certain biomarker testing on blood samples can help to detect heart damage that may occur during chemotherapy.
- Trial name
- NCT01032278
- Testing
- Laboratory Biomarker Analysis, Questionnaires
- Where
- 2 sites in United States
- Volunteers
- 597 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer Therapy-related Cardiovascular Toxicity
Correlation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy
The purpose of this study was to explore the relationship between early myocardial injury caused by tumor drug therapy and intestinal microbial structure changes by echocardiographic two-dimensional speckle tracking technique and…
- Trial name
- NCT05728788
- Testing
- Antitumor drugs
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University Third Hospital
Anthracycline-induced Cardiac Toxicity, Breast Cancer
Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients
This study, called "ROSUBREAST", is a multicenter, double-blind, randomized clinical trial evaluating whether rosuvastatin (20 mg daily) can protect the heart in women with breast cancer receiving anthracycline-based…
- Conditions
- Anthracycline-induced Cardiac Toxicity, Breast Cancer, Anthracycline Related Cardiotoxicity in Breast Cancer, Anthracycline-induced Cardiotoxicity
- Trial name
- ROSUBREAST (NCT07254221)
- Testing
- Rosuvastatin 20 mg/day
- Where
- 7 sites in Iran
- Volunteers
- 400 people
- Sponsor
- Shiraz University of Medical Sciences
Breast Cancer
Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy
The activity of trastuzumab in early-stage, HER2-positive breast cancer, has been demonstrated in many studies, with meta-analyses showing that in combination with a variety of chemotherapy backbones, trastuzumab reduces the risk…
- Trial name
- NCT04928261
- Testing
- Trastuzumab
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- Ottawa Hospital Research Institute
Chronic Myeloproliferative Disorders, Leukemia
A Standardized Nursing Intervention Protocol for HCT Patients
RATIONALE: Visiting patients at home to teach them about self care after a stem cell transplant may be more effective than standard therapy in improving quality of life.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00951626
- Testing
- exercise intervention, telephone-based intervention, dietary intervention
- Where
- United States
- Volunteers
- 282 people
- Sponsor
- City of Hope Medical Center
Heart Failure, Cardiotoxicity
The STOP-MED CTRCD Trial
Cancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cancer therapy which can occur as commonly as in 1 in 5 patients.
- Conditions
- Heart Failure, Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity
- Trial name
- STOP-MED CTRCD (NCT06183437)
- Testing
- Stopping Heart Failure Medication(s)
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 335 people
- Sponsor
- Dinesh Thavendiranathan
Coronary Artery Disease, Cardiac Disease
The CAROLE (CArdiac Related Oncologic Late Effects) Study
CAROLE seeks to evaluate the relationship between chest Radiation Therapy and coronary artery disease. The purpose of CAROLE is to check the heart health of women who received breast cancer treatments in the past and protect them…
- Conditions
- Coronary Artery Disease, Cardiac Disease, Cardiac Toxicity, Radiation
- Trial name
- CAROLE (NCT03235427)
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Northwell Health